Drugs / Artemisia Annua Leaf
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07819825 | Sep 2026 → May 2027 expected | Plasmodium falciparum malaria | Centre de Recherche Médicale de Lambaréné | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04530617 Comparator | Oct 2020 → Jun 2021 | COVID-19, diabetes mellitus, hypertensive disorder, obesity disorder | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Artemisia Annua Leaf | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04530617 ↗ |
| Route | Oral | “drink Artemisia annua infusion over seven days” NCT07819825 ↗ |